CRDL vs. WEED, GUD, ACB, FIRE, OGI, EPI, ICC, CPH, RIV, and LEAF
Should you be buying Cardiol Therapeutics stock or one of its competitors? The main competitors of Cardiol Therapeutics include Canopy Growth (WEED), Knight Therapeutics (GUD), Aurora Cannabis (ACB), Supreme Cannabis (FIRE), Organigram (OGI), ESSA Pharma (EPI), ICC Labs (ICC), Cipher Pharmaceuticals (CPH), RIV Capital (RIV), and Leaf Mobile (LEAF). These companies are all part of the "drug manufacturers - specialty & generic" industry.
Canopy Growth (TSE:WEED) and Cardiol Therapeutics (TSE:CRDL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, dividends, media sentiment, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.
In the previous week, Canopy Growth had 4 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 5 mentions for Canopy Growth and 1 mentions for Cardiol Therapeutics. Cardiol Therapeutics' average media sentiment score of 1.02 beat Canopy Growth's score of 0.00 indicating that Canopy Growth is being referred to more favorably in the media.
14.0% of Canopy Growth shares are held by institutional investors. Comparatively, 13.0% of Cardiol Therapeutics shares are held by institutional investors. 0.3% of Canopy Growth shares are held by insiders. Comparatively, 4.4% of Cardiol Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Cardiol Therapeutics has lower revenue, but higher earnings than Canopy Growth. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.
Canopy Growth has a beta of 1.85, meaning that its stock price is 85% more volatile than the S&P 500. Comparatively, Cardiol Therapeutics has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500.
Canopy Growth presently has a consensus price target of C$6.88, indicating a potential downside of 31.86%. Given Cardiol Therapeutics' higher probable upside, research analysts clearly believe Canopy Growth is more favorable than Cardiol Therapeutics.
Canopy Growth received 631 more outperform votes than Cardiol Therapeutics when rated by MarketBeat users. However, 69.23% of users gave Cardiol Therapeutics an outperform vote while only 62.20% of users gave Canopy Growth an outperform vote.
Canopy Growth's return on equity of -92.11% beat Cardiol Therapeutics' return on equity.
Summary
Canopy Growth beats Cardiol Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Cardiol Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRDL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRDL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cardiol Therapeutics Competitors List
Related Companies and Tools
